SAN

89.31

-0.28%↓

SHL.DE

48.15

-1.23%↓

ARGX

486.7

+0.43%↑

FRE

42.15

-0.24%↓

ONC.US

219.73

-1.77%↓

SAN

89.31

-0.28%↓

SHL.DE

48.15

-1.23%↓

ARGX

486.7

+0.43%↑

FRE

42.15

-0.24%↓

ONC.US

219.73

-1.77%↓

SAN

89.31

-0.28%↓

SHL.DE

48.15

-1.23%↓

ARGX

486.7

+0.43%↑

FRE

42.15

-0.24%↓

ONC.US

219.73

-1.77%↓

SAN

89.31

-0.28%↓

SHL.DE

48.15

-1.23%↓

ARGX

486.7

+0.43%↑

FRE

42.15

-0.24%↓

ONC.US

219.73

-1.77%↓

SAN

89.31

-0.28%↓

SHL.DE

48.15

-1.23%↓

ARGX

486.7

+0.43%↑

FRE

42.15

-0.24%↓

ONC.US

219.73

-1.77%↓

Search

Laboratorios Farmaceuticos Rovi SA

Closed

SectorHealthcare

52.35 -2.24

Overview

Share price change

24h

Current

Min

52.55

Max

53.75

Key metrics

By Trading Economics

Income

-57M

32M

Sales

199M

434M

P/E

Sector Avg

20.225

56.602

EPS

0.457

Dividend yield

2.15

Profit margin

7.411

Employees

2,197

EBITDA

40M

138M

Recommendations

By TipRanks

Recommendations

Buy

12 Months Forecast

+45.46% upside

Dividends

By Dow Jones

Dividend yield

Sector Avg

2.15%

2.45%

Next Earnings

30 lip 2025

Market Stats

By TradingEconomics

Market Cap

-643M

2.8B

Previous open

54.59

Previous close

52.35

News Sentiment

By Acuity

50%

50%

187 / 382 Ranking in Healthcare

Technical Score

By Trading Central

Confidence

Weak Bullish Evidence

Laboratorios Farmaceuticos Rovi SA Chart

Wyniki osiągnięte w przeszłości nie są gwarantem przyszłych wyników.

Related News

14 maj 2025, 23:40 UTC

Hot Stocks

Stocks to Watch: UnitedHealth Group, Foot Locker, CoreWeave

14 maj 2025, 23:33 UTC

Major Market Movers

UnitedHealth Group Shares Fall After WSJ Reports of Investigation for Possible Medicare Fraud

14 maj 2025, 23:25 UTC

Major Market Movers

Biohaven Shares Down as FDA Extends PDUFA Data for Troriluzole

14 maj 2025, 23:25 UTC

Earnings

Xero Lifts Fiscal Year Profit 30% on Higher Prices, Subscriber Growth -- Update

14 maj 2025, 22:58 UTC

Earnings

Xero Lifts Fiscal Year Profit 30% on Higher Prices, Subscriber Growth

14 maj 2025, 21:35 UTC

Earnings

Cisco Systems Names Patterson as CFO, Patel as President

14 maj 2025, 23:59 UTC

Market Talk

Implications of Xero's Cost Outlook Aren't Clear -- Market Talk

14 maj 2025, 23:49 UTC

Market Talk

Xero's Cost Outlook Likely to Prompt Downgrades -- Market Talk

14 maj 2025, 23:48 UTC

Market Talk

Global Equities Roundup: Market Talk

14 maj 2025, 23:48 UTC

Market Talk

Nikkei May Decline on Profit-Taking After Recent Gains -- Market Talk

14 maj 2025, 23:47 UTC

Market Talk

Gold Gains on Possible Technical Recovery -- Market Talk

14 maj 2025, 23:34 UTC

Acquisitions, Mergers, Takeovers

Agnico-Eagle Mines to Subscribe for 30M Voting Common Shares of Foran Mining in Non-Brokered Private Placement at C$3 a Share

14 maj 2025, 23:10 UTC

Earnings

Xero Lifts FY Profit 30% on Higher Prices, Subscriber Growth -- Update

14 maj 2025, 23:07 UTC

Earnings

CoreWeave Posts Strong Revenue and Wins Google as a Customer. Stock Still Dives on Outlook. -- Barrons.com

14 maj 2025, 23:00 UTC

Top News

UnitedHealth Group Is Under Criminal Investigation for Possible Medicare Fraud -- WSJ

14 maj 2025, 22:43 UTC

Earnings

Xero Lifts FY Profit 30% on Higher Prices, Subscriber Growth

14 maj 2025, 22:34 UTC

Earnings

Xero Expects 1H Operating Expense Ratio to Be Higher Than 2H>XRO.AU

14 maj 2025, 22:33 UTC

Earnings

Xero Expects FY26 Operating Expense Ratio of 71.5%>XRO.AU

14 maj 2025, 22:30 UTC

Earnings

Xero Did Not Declare a Dividend>XRO.AU

14 maj 2025, 22:30 UTC

Earnings

Xero FY Operating Expenses 71.8% of Operating Revenue Vs. 73.3%>XRO.AU

14 maj 2025, 22:30 UTC

Earnings

Xero FY Free Cashflow Margin 24.1% Vs. 20.0%>XRO.AU

14 maj 2025, 22:30 UTC

Earnings

Xero FY Free Cashflow NZD506.7M Vs. NZD342.1M>XRO.AU

14 maj 2025, 22:28 UTC

Earnings

Xero FY Ebitda NZD638.5M Vs. NZD497.4M>XRO.AU

14 maj 2025, 22:28 UTC

Earnings

Xero FY Adjusted Ebitda NZD640.6M Vs. NZD526.5M>XRO.AU

14 maj 2025, 22:27 UTC

Earnings

Xero FY Rev NZD2.10B Vs. NZD1.71B >XRO.AU

14 maj 2025, 22:27 UTC

Earnings

Xero FY Net NZD227.8M Vs. Net NZD174.6M >XRO.AU

14 maj 2025, 22:23 UTC

Top News

Boeing, GE Aerospace Get Qatar Airways Order After Saudi AI Tech Deals -- 2nd Update

14 maj 2025, 22:15 UTC

Earnings

Correction to Cisco Earnings Article -- WSJ

14 maj 2025, 21:48 UTC

Earnings

CoreWeave Posts Strong Revenue but Stock Dives on Updated Outlook -- Barrons.com

14 maj 2025, 21:37 UTC

Earnings

Cisco Reports Solid Earnings. The Stock Is Rising. -- Barrons.com

Peer Comparison

Price change

Laboratorios Farmaceuticos Rovi SA Forecast

Price Target

By TipRanks

45.46% upside

12 Months Forecast

Average 77.75 EUR  45.46%

High 90 EUR

Low 65.5 EUR

Based on 2 Wall Street analysts offering 12 month price targets forLaboratorios Farmaceuticos Rovi SA - Dist in the last 3 months.

Rating Consensus

By TipRanks

Buy

2 ratings

2

Buy

0

Hold

0

Sell

Technical Score

By Trading Central

51.1 / N/ASupport & Resistance

Short Term

Weak Bullish Evidence

Intermediate Term

Strong Bullish Evidence

Long Term

Weak Bearish Evidence

Sentiment

By Acuity

187 / 382 Ranking in Healthcare

News Sentiment

Neutral

Volatility

Below average

News Volume (RCV)

Below average

Financials

Selling and administration expenses

Operating expenses

Pre-tax profit

Sales

Cost of sales

Gross profit on sales

Interest expense on debt

EBITDA

Operating profit

$

About Laboratorios Farmaceuticos Rovi SA

Laboratorios Farmaceuticos Rovi, S.A. engages in the research, development, manufacture, and marketing of pharmaceutical products in Spain and internationally. The company provides products for cardiology, osteoarticular/women's health, anesthesia /pain, diagnostic imaging contrast agents, central nervous system, urology, endocrinology, respiratory, and primary healthcare areas. Its principal products include Ameride, Bertanel, Bluxam, Enoxaparin Rovi, Calcium Vitamine D3 Rovi, Exxiv, Prinvil, Rhodogil, Glufan, Hibor, Hirobriz Breezhaler, Neparvis, Medicebran, Medikinet, Mysimba, Orvatez, Tryptizol, Ulunar Breezhaler, and Volutsa; and hospital products, such as Iomeron and Iopamiro, Multihance and Y Prohance, Sonovue, Empowercta+, Empowermr, and CT Express, Fibrilin, and Sodium Heparin Rovi. It also provides contract-manufacturing services to other companies for a range of pharmaceutical forms, including prefilled syringes, vials, suppositories, tablets, and sachets. Laboratorios Farmaceuticos Rovi, S.A. was incorporated in 1946 and is headquartered in Madrid, Spain. Laboratorios Farmaceúticos Rovi, S.A. is a subsidiary of Norbel Inversiones, S.L.